Effects of Dienogest Therapy on Endometriosis-Related Dysmenorrhea, Dyspareunia, and Endometrioma Size
Endometriosis is an estrogen-dependent chronic inflammatory disease that is defined by the presence of endometrial-like tissue outside of the uterus. The most common localization is the ovaries, and endometriosis in this location is then called an endometrioma. According to the European Society of H...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-01, Vol.15 (1), p.e34162-e34162 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e34162 |
|---|---|
| container_issue | 1 |
| container_start_page | e34162 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Saglik Gokmen, Bilgehan Topbas Selcuki, Nura F Aydın, Alev Yalcin Bahat, Pinar Akça, Aysu |
| description | Endometriosis is an estrogen-dependent chronic inflammatory disease that is defined by the presence of endometrial-like tissue outside of the uterus. The most common localization is the ovaries, and endometriosis in this location is then called an endometrioma. According to the European Society of Human Reproduction and Embryology (ESHRE) (2022) guidelines, the most commonly prescribed treatments for endometriosis include drugs that alter the hormonal milieu. Dienogest is a new generation of progestin used in the treatment of endometriosis. The aim of this study was to assess the effect of Dienogest treatment on endometrioma size and endometriosis-related pain symptoms over a six-month follow-up period.
This prospective observational study was conducted at a tertiary clinic in Turkey between March 2020 and March 2021. Here, 64 patients aged 17-49 years with unilateral or bilateral endometriomas without any hormone-dependent cancers and any medical conditions contraindicating the onset of hormonal treatment, such as active venous thromboembolism, previous or current cardiovascular disease, diabetes with cardiovascular complications, current severe liver disease, and not being pregnant, were included. Endometrioma sizes were determined by transvaginal ultrasonography (TVUS). Dysmenorrhea and dyspareunia symptoms were evaluated using the visual analogue scale (VAS). Patients received Dienogest 2 mg/day continuously for six months. At the three- and six-month follow-ups, the patients were re-evaluated.
The mean endometrioma size decreased significantly from an initial measurement of 44.0 ± 13 mm to 39.5 ± 15 mm at three months and to 34.4 ± 18 mm at the six-month follow-up. The mean dysmenorrhea VAS scores before treatment, at the three-month follow-up, and at the six-month follow-up were 6.9 ± 2.6, 4.3 ± 2.8, and 3.8 ± 2.7, respectively. Dysmenorrhea VAS scores decreased significantly over the first three months (p |
| doi_str_mv | 10.7759/cureus.34162 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9949989</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780482778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-bc9e52afc9b53a1ea0fd34c7c087afe4852c10561395718a705d45ac64cb0c4d3</originalsourceid><addsrcrecordid>eNpdkc9LHDEUx0OpVNl667kM9NKDY_NzklwKRbe1IAhqzyGbeXEjM8k2mRG2f32jq7LtKe_xPvnyfe-L0AeCT6UU-oubM8zllHHS0TfoiJJOtYoo_navPkTHpdxjjAmWFEv8Dh2yTnGmGD1Cfuk9uKk0yTfnAWK6gzI1t2vIdrNtUmyWsU8jTDmkEkp7DYOdoG_Ot2WscM5rsCeP3cZWIzHUxsZ-79Nom5vwB96jA2-HAsfP7wL9-r68PbtoL69-_Dz7dtk6xunUrpwGQa13eiWYJWCx7xl30mElrQeuBHUEi44wLSRRVmLRc2Fdx90KO96zBfq6093MqxF6B3HKdjCbHEabtybZYP6dxLA2d-nBaM21VroKfH4WyOn3XG9hxlAcDIONkOZiqFSYKyqlquin_9D7NOdY13uiOoFJNbpAJzvK5VRKBv9qhmDzmKHZZWieMqz4x_0FXuGXxNhf6n2aeQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780650161</pqid></control><display><type>article</type><title>Effects of Dienogest Therapy on Endometriosis-Related Dysmenorrhea, Dyspareunia, and Endometrioma Size</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Saglik Gokmen, Bilgehan ; Topbas Selcuki, Nura F ; Aydın, Alev ; Yalcin Bahat, Pinar ; Akça, Aysu</creator><creatorcontrib>Saglik Gokmen, Bilgehan ; Topbas Selcuki, Nura F ; Aydın, Alev ; Yalcin Bahat, Pinar ; Akça, Aysu</creatorcontrib><description>Endometriosis is an estrogen-dependent chronic inflammatory disease that is defined by the presence of endometrial-like tissue outside of the uterus. The most common localization is the ovaries, and endometriosis in this location is then called an endometrioma. According to the European Society of Human Reproduction and Embryology (ESHRE) (2022) guidelines, the most commonly prescribed treatments for endometriosis include drugs that alter the hormonal milieu. Dienogest is a new generation of progestin used in the treatment of endometriosis. The aim of this study was to assess the effect of Dienogest treatment on endometrioma size and endometriosis-related pain symptoms over a six-month follow-up period.
This prospective observational study was conducted at a tertiary clinic in Turkey between March 2020 and March 2021. Here, 64 patients aged 17-49 years with unilateral or bilateral endometriomas without any hormone-dependent cancers and any medical conditions contraindicating the onset of hormonal treatment, such as active venous thromboembolism, previous or current cardiovascular disease, diabetes with cardiovascular complications, current severe liver disease, and not being pregnant, were included. Endometrioma sizes were determined by transvaginal ultrasonography (TVUS). Dysmenorrhea and dyspareunia symptoms were evaluated using the visual analogue scale (VAS). Patients received Dienogest 2 mg/day continuously for six months. At the three- and six-month follow-ups, the patients were re-evaluated.
The mean endometrioma size decreased significantly from an initial measurement of 44.0 ± 13 mm to 39.5 ± 15 mm at three months and to 34.4 ± 18 mm at the six-month follow-up. The mean dysmenorrhea VAS scores before treatment, at the three-month follow-up, and at the six-month follow-up were 6.9 ± 2.6, 4.3 ± 2.8, and 3.8 ± 2.7, respectively. Dysmenorrhea VAS scores decreased significantly over the first three months (p<0.01). Similarly, the mean VAS score for dyspareunia decreased at three and six months compared with the pretreatment value (p<0.01).
This study shows that dienogest treatment reduced the symptoms of dysmenorrhea and dyspareunia and the size of endometriomas. However, the main significant decrease in dysmenorrhea and dyspareunia symptoms was noted in the first three months, making it a good treatment option, especially in young patients with a fertility wish.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.34162</identifier><identifier>PMID: 36843832</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Body mass index ; Cysts ; Endometriosis ; Fertility ; Gynecology ; Infertility ; Localization ; Magnetic resonance imaging ; Obstetrics/Gynecology ; Ovaries ; Pain ; Patients ; Ultrasonic imaging</subject><ispartof>Curēus (Palo Alto, CA), 2023-01, Vol.15 (1), p.e34162-e34162</ispartof><rights>Copyright © 2023, Saglik Gokmen et al.</rights><rights>Copyright © 2023, Saglik Gokmen et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Saglik Gokmen et al. 2023 Saglik Gokmen et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-bc9e52afc9b53a1ea0fd34c7c087afe4852c10561395718a705d45ac64cb0c4d3</citedby><cites>FETCH-LOGICAL-c342t-bc9e52afc9b53a1ea0fd34c7c087afe4852c10561395718a705d45ac64cb0c4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949989/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949989/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36843832$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saglik Gokmen, Bilgehan</creatorcontrib><creatorcontrib>Topbas Selcuki, Nura F</creatorcontrib><creatorcontrib>Aydın, Alev</creatorcontrib><creatorcontrib>Yalcin Bahat, Pinar</creatorcontrib><creatorcontrib>Akça, Aysu</creatorcontrib><title>Effects of Dienogest Therapy on Endometriosis-Related Dysmenorrhea, Dyspareunia, and Endometrioma Size</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Endometriosis is an estrogen-dependent chronic inflammatory disease that is defined by the presence of endometrial-like tissue outside of the uterus. The most common localization is the ovaries, and endometriosis in this location is then called an endometrioma. According to the European Society of Human Reproduction and Embryology (ESHRE) (2022) guidelines, the most commonly prescribed treatments for endometriosis include drugs that alter the hormonal milieu. Dienogest is a new generation of progestin used in the treatment of endometriosis. The aim of this study was to assess the effect of Dienogest treatment on endometrioma size and endometriosis-related pain symptoms over a six-month follow-up period.
This prospective observational study was conducted at a tertiary clinic in Turkey between March 2020 and March 2021. Here, 64 patients aged 17-49 years with unilateral or bilateral endometriomas without any hormone-dependent cancers and any medical conditions contraindicating the onset of hormonal treatment, such as active venous thromboembolism, previous or current cardiovascular disease, diabetes with cardiovascular complications, current severe liver disease, and not being pregnant, were included. Endometrioma sizes were determined by transvaginal ultrasonography (TVUS). Dysmenorrhea and dyspareunia symptoms were evaluated using the visual analogue scale (VAS). Patients received Dienogest 2 mg/day continuously for six months. At the three- and six-month follow-ups, the patients were re-evaluated.
The mean endometrioma size decreased significantly from an initial measurement of 44.0 ± 13 mm to 39.5 ± 15 mm at three months and to 34.4 ± 18 mm at the six-month follow-up. The mean dysmenorrhea VAS scores before treatment, at the three-month follow-up, and at the six-month follow-up were 6.9 ± 2.6, 4.3 ± 2.8, and 3.8 ± 2.7, respectively. Dysmenorrhea VAS scores decreased significantly over the first three months (p<0.01). Similarly, the mean VAS score for dyspareunia decreased at three and six months compared with the pretreatment value (p<0.01).
This study shows that dienogest treatment reduced the symptoms of dysmenorrhea and dyspareunia and the size of endometriomas. However, the main significant decrease in dysmenorrhea and dyspareunia symptoms was noted in the first three months, making it a good treatment option, especially in young patients with a fertility wish.</description><subject>Body mass index</subject><subject>Cysts</subject><subject>Endometriosis</subject><subject>Fertility</subject><subject>Gynecology</subject><subject>Infertility</subject><subject>Localization</subject><subject>Magnetic resonance imaging</subject><subject>Obstetrics/Gynecology</subject><subject>Ovaries</subject><subject>Pain</subject><subject>Patients</subject><subject>Ultrasonic imaging</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc9LHDEUx0OpVNl667kM9NKDY_NzklwKRbe1IAhqzyGbeXEjM8k2mRG2f32jq7LtKe_xPvnyfe-L0AeCT6UU-oubM8zllHHS0TfoiJJOtYoo_navPkTHpdxjjAmWFEv8Dh2yTnGmGD1Cfuk9uKk0yTfnAWK6gzI1t2vIdrNtUmyWsU8jTDmkEkp7DYOdoG_Ot2WscM5rsCeP3cZWIzHUxsZ-79Nom5vwB96jA2-HAsfP7wL9-r68PbtoL69-_Dz7dtk6xunUrpwGQa13eiWYJWCx7xl30mElrQeuBHUEi44wLSRRVmLRc2Fdx90KO96zBfq6093MqxF6B3HKdjCbHEabtybZYP6dxLA2d-nBaM21VroKfH4WyOn3XG9hxlAcDIONkOZiqFSYKyqlquin_9D7NOdY13uiOoFJNbpAJzvK5VRKBv9qhmDzmKHZZWieMqz4x_0FXuGXxNhf6n2aeQ</recordid><startdate>20230124</startdate><enddate>20230124</enddate><creator>Saglik Gokmen, Bilgehan</creator><creator>Topbas Selcuki, Nura F</creator><creator>Aydın, Alev</creator><creator>Yalcin Bahat, Pinar</creator><creator>Akça, Aysu</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230124</creationdate><title>Effects of Dienogest Therapy on Endometriosis-Related Dysmenorrhea, Dyspareunia, and Endometrioma Size</title><author>Saglik Gokmen, Bilgehan ; Topbas Selcuki, Nura F ; Aydın, Alev ; Yalcin Bahat, Pinar ; Akça, Aysu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-bc9e52afc9b53a1ea0fd34c7c087afe4852c10561395718a705d45ac64cb0c4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Body mass index</topic><topic>Cysts</topic><topic>Endometriosis</topic><topic>Fertility</topic><topic>Gynecology</topic><topic>Infertility</topic><topic>Localization</topic><topic>Magnetic resonance imaging</topic><topic>Obstetrics/Gynecology</topic><topic>Ovaries</topic><topic>Pain</topic><topic>Patients</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saglik Gokmen, Bilgehan</creatorcontrib><creatorcontrib>Topbas Selcuki, Nura F</creatorcontrib><creatorcontrib>Aydın, Alev</creatorcontrib><creatorcontrib>Yalcin Bahat, Pinar</creatorcontrib><creatorcontrib>Akça, Aysu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saglik Gokmen, Bilgehan</au><au>Topbas Selcuki, Nura F</au><au>Aydın, Alev</au><au>Yalcin Bahat, Pinar</au><au>Akça, Aysu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Dienogest Therapy on Endometriosis-Related Dysmenorrhea, Dyspareunia, and Endometrioma Size</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-01-24</date><risdate>2023</risdate><volume>15</volume><issue>1</issue><spage>e34162</spage><epage>e34162</epage><pages>e34162-e34162</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Endometriosis is an estrogen-dependent chronic inflammatory disease that is defined by the presence of endometrial-like tissue outside of the uterus. The most common localization is the ovaries, and endometriosis in this location is then called an endometrioma. According to the European Society of Human Reproduction and Embryology (ESHRE) (2022) guidelines, the most commonly prescribed treatments for endometriosis include drugs that alter the hormonal milieu. Dienogest is a new generation of progestin used in the treatment of endometriosis. The aim of this study was to assess the effect of Dienogest treatment on endometrioma size and endometriosis-related pain symptoms over a six-month follow-up period.
This prospective observational study was conducted at a tertiary clinic in Turkey between March 2020 and March 2021. Here, 64 patients aged 17-49 years with unilateral or bilateral endometriomas without any hormone-dependent cancers and any medical conditions contraindicating the onset of hormonal treatment, such as active venous thromboembolism, previous or current cardiovascular disease, diabetes with cardiovascular complications, current severe liver disease, and not being pregnant, were included. Endometrioma sizes were determined by transvaginal ultrasonography (TVUS). Dysmenorrhea and dyspareunia symptoms were evaluated using the visual analogue scale (VAS). Patients received Dienogest 2 mg/day continuously for six months. At the three- and six-month follow-ups, the patients were re-evaluated.
The mean endometrioma size decreased significantly from an initial measurement of 44.0 ± 13 mm to 39.5 ± 15 mm at three months and to 34.4 ± 18 mm at the six-month follow-up. The mean dysmenorrhea VAS scores before treatment, at the three-month follow-up, and at the six-month follow-up were 6.9 ± 2.6, 4.3 ± 2.8, and 3.8 ± 2.7, respectively. Dysmenorrhea VAS scores decreased significantly over the first three months (p<0.01). Similarly, the mean VAS score for dyspareunia decreased at three and six months compared with the pretreatment value (p<0.01).
This study shows that dienogest treatment reduced the symptoms of dysmenorrhea and dyspareunia and the size of endometriomas. However, the main significant decrease in dysmenorrhea and dyspareunia symptoms was noted in the first three months, making it a good treatment option, especially in young patients with a fertility wish.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36843832</pmid><doi>10.7759/cureus.34162</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-01, Vol.15 (1), p.e34162-e34162 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9949989 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Body mass index Cysts Endometriosis Fertility Gynecology Infertility Localization Magnetic resonance imaging Obstetrics/Gynecology Ovaries Pain Patients Ultrasonic imaging |
| title | Effects of Dienogest Therapy on Endometriosis-Related Dysmenorrhea, Dyspareunia, and Endometrioma Size |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T02%3A37%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Dienogest%20Therapy%20on%20Endometriosis-Related%20Dysmenorrhea,%20Dyspareunia,%20and%20Endometrioma%20Size&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Saglik%20Gokmen,%20Bilgehan&rft.date=2023-01-24&rft.volume=15&rft.issue=1&rft.spage=e34162&rft.epage=e34162&rft.pages=e34162-e34162&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.34162&rft_dat=%3Cproquest_pubme%3E2780482778%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2780650161&rft_id=info:pmid/36843832&rfr_iscdi=true |